% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • opinionscincy opinionscincy Mar 21, 2012 5:02 PM Flag


    Breast cancer is one of the most common forms of cancer and is a disease with few options regarding treatment. Just look at Roche-Genetech's (RHHBY.PK); the company's drug Herceptin is one of the few advanced treatments for breast cancer patients, but only treats 25% of those diagnosed. NeuVax is believed to treat up to 75% (50% for sure) and with Herceptin returning $5 billion in annual sales, and only targeting 25% of patients, I think it is obvious why investors are so excited regarding the potential market for NeuVax.

    In addition to having a massive potential market, its production of NeuVax is quite low. NeuVax is produced for less than $1,000 per dose, which reflects the potential for very large margins considering Dendreon's (DNDN) Provenge which has an off-the-shelf product being produced for roughly $20,000. Therefore, with a solid product, a large market, and a low production cost I think it is obvious why I deemed the stock as the best value based on valuation and potential.

    The stock is no longer an under-the-radar investment with the biotechnology community, and its news on Monday is yet another reason for investors to be excited. The company announced that it had received a patent that covers the use of NeuVax for treating a target population of low to intermediate HER2 patients. This basically means that Galena just received rights to NeuVax, a drug that treats at least double the number of patients as Herceptin, the $5 billion in annual sales drug. It's no wonder the stock jumped 25% on the news. This is a stock that is still valued under $100 million and a patent such as this could be huge for the future of this company (both in sales and attractiveness to big pharma).

0.2829-0.0261(-8.45%)Oct 21 4:00 PMEDT